Flagship commits £100M to set up AI-focused biotech incubation outpost in London

Noubar Afeyan, Flagship Pioneering Moderna
Flagship CEO Noubar Afeyan, Ph.D., told Fierce earlier this year that the company was “looking at opportunities that will expand our network presence globally in certain important hubs.” (Flagship Pioneering)

Flagship Pioneering has picked London as the site of the venture capital powerhouse’s first company-creation unit outside of its hometown.

The Flagship Origination Lab, U.K., will “conceive, test, fund and build AI-native platform companies that advance human and planetary health and other frontiers of science and technology,” the company explained in a Nov. 16 release.

Flagship has committed an initial 100 million pounds ($132 million) to launch the lab, which will include recruiting and training an initial team of around 50 scientist-entrepreneurs and operators in the U.K. It is the first time that Flagship has expanded its biotech creation model beyond its home of Cambridge, Massachusetts, the company noted.

The idea is to create a “locally rooted company-creation ecosystem in the U.K., connected to Flagship’s broader global ecosystem,” such as its portfolio of companies as well as its AI platform Pioneering Intelligence and its in-house drug discovery and development unit Pioneering Medicines.

Flagship’s announcement came on the first day of London Life Sciences Week. The company’s relationship with the U.K. dates back to 2023, when Flagship signed a memorandum of understanding with the government.

Earlier in the year, Flagship Founder and CEO Noubar Afeyan, Ph.D., told Fierce that the company was “looking at opportunities that will expand our network presence globally in certain important hubs, where we find complementary resources, namely talent, but also capital [and] partnerships.”

“That's certainly the case in the U.K. and in Asia Pacific,” said Afeyan at the time, who also name-checked Flagship’s work building networks in the Gulf.

In this morning’s release, Afeyan explained that the London lab “marks the beginning of a new chapter in Flagship’s relationship with the U.K.” 

“Over the past three years, we have seen firsthand the extraordinary depth of scientific imagination, talent and ambition across the country,” the CEO added. “With our 100 million pound initial commitment, which we anticipate scaling through partnership to attract an additional 500 million pounds, we are now making a long-term commitment to build on that foundation.”

Chris McDonald, the U.K. government minister for science, innovation and investment, used Flagship’s release to describe the U.K. as a “natural home for AI and life sciences companies.”

“We want to see more new businesses across these sectors turning cutting-edge research and technology into new jobs and economic growth,” McDonald said in a statement. “This new commitment from Flagship Pioneering will kick-start companies of the future in the U.K., who will take breakthroughs in AI and life sciences to the rest of the world and deliver innovations that can save lives.” 

Since launching in 2000, Flagship has helped originate over 100 scientific ventures. The company's current ecosystem spans over 40 entities, including the likes of Moderna, Generate Biomedicines, Tessera Therapeutics and Valo Health.

Flagship’s decision marks another welcome show of faith in U.K. life sciences R&D following a tough period for the sector that saw the likes of AstraZeneca, Merck & Co., Eli Lilly and Sanofi reverse or pause R&D investments in the country last year over concerns regarding a medicine price reimbursement scheme.

While the government’s amendments to those rules, along with a deal with the Trump administration, were enough to persuade Cambridge-headquartered AstraZeneca to unfreeze its investments earlier this year, the likes of Merck, Sanofi and Lilly told Fierce recently that their overall stance hasn’t shifted.

Still, there has been other good news in recent weeks courtesy of AbbVie investing 120 million pounds ($160 million) to expand its U.K. R&D presence, as well as Moderna moving its U.K. base to a different part of London.